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Background: The relevance of recurrent molecular abnormalities in cytogenetically normal (CN) acute myeloid
leukemia (AML) was recently acknowledged by the inclusion of molecular markers such as NPM1, FLT3, and CEBPA as a
complement to cytogenetic information within both the World Health Organization and the European Leukemia Net
classifications. Mitochondrial metabolism is different in cancer and normal cells. A novel cytosolic type 2-hydroxybutyrate
dehydrogenase, BDH2, originally named DHRS6, plays a physiological role in the cytosolic utilization of ketone bodies,
which can subsequently enter mitochondria and the tricarboxylic acid cycle. Moreover, BDH2 catalyzes the production of
2, 3-DHBA during enterobactin biosynthesis and participates in 24p3 (LCN2)-mediated iron transport and apoptosis.
Results: We observed that BDH2 expression is an independent poor prognostic factor for CN-AML, with an anti-apoptotic
role. Patients with high BDH2 expression have relatively shorter overall survival (P = 0.007) and a low complete response
rate (P = 0.032). BDH2-knockdown (BDH2-KD) in THP1 and HL60 cells increased the apoptosis rate under reactive oxygen
species stimulation. Decrease inducible survivin, a member of the inhibitors of apoptosis family, but not members of the
Bcl-2 family, induced apoptosis via a caspase-3-independent pathway upon BDH2-KD.
Conclusions: BDH2 is a novel independent poor prognostic marker for CN-AML, with the role of anti-apoptosis, through
surviving.
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While morphological evaluation of bone marrow (BM)
and blood remains a cornerstone for the diagnosis of acute
myeloid leukemia (AML), the presence or absence of spe-
cific cytogenetic and molecular abnormalities is useful not
only for determining overall prognosis but also for
guiding treatment. Clonal chromosomal aberrations
are not detected in 40–50% of patients [1]. Both the
World Health Organization and the European Leukemia
Net classifications have included molecular markers such* Correspondence: shlin@kmu.edu.tw
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reproduction in any medium, provided the ornormal-acute myeloid leukemia (CN-AML) reinforcing
their importance in cytogenetics [2,3]. Other mutated
genes (e.g., WT1, IDH1/IDH2, TET2, RUNX1, and MLL)
or aberrantly expressed ones (e.g., BAALC, ERG, EVI1,
and miR-181a) will likely become useful in refining mo-
lecular risk in CN-AML [4-16]. Mithat Gönen et al.
reported a panel of genetic profile that related to progno-
sis of AML [17].
In 1926, Otto Warburg initiated research on mito-
chondrial alterations in cancer and proposed a mechan-
ism to explain the differences in energy metabolism
between normal and cancer cells, suggesting that mito-
chondrial alterations could provide unique therapeutic
targets in various cancer types [18]. Understanding the
existing cross-talk between cellular metabolism and
growth control has resulted in a better understanding of
normal and disease processes and has facilitated thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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example, trastuzumab and imatinib [19,20].
Guo et al. identified BDH2 as a short-chain dehydrogen-
ase/reductase family member, originally named as DHRS6
[21] BDH2 is a novel cytosolic-type 2-hydroxybutyrate de-
hydrogenase and has a physiological role in the utilization
of cytosolic ketone bodies, which can subsequently enter
mitochondria and the tricarboxylic acid cycle [21]. Re-
cently, Devireddy et al. reported that BDH2 catalyzes the
production of 2,3-DHBA during enterobactin biosynthesis
and participates in 24p3 (LCN2)-mediated iron transport
and apoptosis [22]. We reported that LCN2 expression is
associated with prognosis in CN-AML previously [23].
While BDH2 is a gene related to mitochondria metabol-
ism and participates in LCN2 mediated iron transport and
apoptosis, we have interest to know if BDH2 has prognos-
tic impact on CN-AML.
Here, we analyzed the relationship between BDH2, an
enzyme related to the lipid metabolic pathway and iron
transport, and CN-AML. We assessed whether BDH2 is
a prognostic factor for patient survival. Additionally, we
investigated the mechanism underlying the prognostic
ability of BDH2 by using RNA interference-mediated
knockdown of BDH2 (BDH2-KD) in cell lines.
Methods
Ethics statement
This research was approved by Kaohsiung-Medical
University Chung-Ho Memorial Hospital institutional re-
view boards and ethics committees. All human partici-
pants provided written informed consent.
Patients
We enrolled 130 patients newly diagnosed with CN-
AML from August 2001 to February 2012, in a single
medical center for retrospective analysis. Only 113 pa-
tients (including 49 female and 64 male patients) could
be analyzed because of poor RNA quality in the
remaining 17 samples. The average patient age was 54.5
years (age range, 22–86 years), with 47 patients more
than 60 y/o. We also collected 43 normal BM samples,
defined by normal BM findings in both BM aspiration
smears and biopsy pathology reports and with no cyto-
genetic abnormalities, as a control group. Most patients
were lymphoma without BM involvement. Moreover, we
random collected bone marrow samples with good
RNA quality from 10 newly diagnosed AML patients
with AML-ETO fusion gene (translocation the AML1
[CBFA2, RUNX1] gene in the 21q22 region is fused to
the ETO [MTG8 , RUNX1T] gene in the 8q22 region),
3 patients with cytogenetic finding of inv (16), as a
good risk group, and 25 patients with multiple chro-
mosomes abnormalities (more than 3 abnormalities) as
a poor prognostic group from the samples in the past10 years. Patients with chromosome 8 abnormality was
excluded to avoid contaminated by myelodysplasia
syndrome transformed AML.
Eighty-six CN-AML patients received conventional in-
tensive induction chemotherapy consisting of 7 days of
cytarabine at 200 mg·m−2·day−1 and 3 days of daunorubi-
cin at 45 mg·m−2·day−1 (I3A7). Patients who failed to
achieve complete remission (CR) but attained partial re-
mission received the second induction chemotherapy
with 70% doses of I3A7 under nadir status (between 7
and 10 days after first intensive chemotherapy). Patients
achieving CR received consolidation chemotherapy with
high dose AraC (cytarabine at 1 to 2 g·m−2·day−1 on day
1, 3 and 5). Based on the findings of these patients, we
analyzed clinical outcomes, including overall survival
(OS) and leukemia-free survival (LFS). Patients without
CR after 2 rounds of intensive chemotherapy with good
performance status (Eastern Cooperative Oncology Group,
ECOG 0 or 1) and those with CR with a poor prognostic
factor, including patients with delayed CR and FLT3 in-
ternal tandem duplication (FLT3-ITD) mutation detected
after 2011, received hematopoietic stem cell transplant-
ation (HSCT).
Clinical end points
CR was defined as recovery of morphologically normal
BM and blood counts (i.e., neutrophil count ≥ 1.5 × 109/
L and platelet count ≥ 100 × 109/L) and no circulating
leukemic blasts or evidence of extramedullary leukemia.
Relapse was defined by ≥5% BM blasts, circulating leukemic
blasts, or development of extramedullary leukemia. OS was
measured from the date of initial diagnosis until the date of
death, censoring for patients alive at the last follow-up. LFS
was measured from the date of CR until the date of relapse
or death, regardless of the cause of death, censoring for pa-
tients alive at the last follow-up. Relapse-free survival (RFS)
was measured from the date of diagnosis until the date of
relapse or death.
Quantitative real-time reverse transcriptase-polymerase
chain reaction (qRT-PCR) for mRNA expression analysis
of BDH2, LCN2, Meningionma1 (MN1), ETS-related gene
(ERG), micro-RNA-181a (miR-181a), and micro-RNA-
3151 (miR-3151).
BM samples were collected at first diagnosis, and total
RNA was extracted using the Trizol method (Invitrogen,
Carlsbad, CA, USA). Furthermore, the same method was
used to extract total RNA for RNA interference-mediated
BDH2-KD in THP1 and HL60 cell lines. The RNA input
(2 μg) for cDNA synthesis was determined by OD260
measurement, and cDNA was reverse transcribed using a
TaqMan® High Capacity Reverse Transcription Kit
(Applied Biosystems, Carlsbad, CA, USA) according to
the manufacturer’s protocols. The cDNA sequences of
BDH2 and LCN2 were evaluated, and the specific
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designed using Primer Express software version 1.5
(Applied Biosystems). The TaqMan® MGB probe designed
by the software was synthesized and labeled with FAM
fluorescent dye (Applied Biosystems). The mRNA expres-
sion levels of BDH2 and LCN2 were analyzed by qRT-
PCR with the following primer sets and probes. BDH2:
forward primer 5′-TTC CAG CGT CAA AGG AGT
TGT-3′, reverse primer 5′-TTC CTG GGC ACA CAC
AGT TG-3′, TaqMan® MGB probe 5′-ACA GAT GTG
TGT GTA CAG CAC-3′ and LCN2: forward primer 5′-
GGT ATG TGG TAG GCC TGG CA-3′, reverse primer
5′-AAC AGG ACG GAG GTG ACA TTG T-3′, TaqMan®
MGB probe 5′-ACC CGC AAA AGA TGT A-3′. Expres-
sion of human β-actin was used to normalize BDH2,
LCN2, ERG and MN1gene expression in qRT-PCR.
Expression of human U6 snRNA was used to normalized
miRNA181a and miRNA3151 gene expression in qRT-
PCR. This TaqMan® endogenous control and primers and
TaqMan® probes of ERG1, MN1, miRNA-181a and
miRNA-3151 were purchased from Applied Biosystems. All
reactions were carried out in a 25-μL final volume
containing 200 ng of cDNA (as total input RNA), 400 nM
of each primer, 200 nM of probe, and 12.5 μL of 2X
TaqMan® Universal PCR Master Mix (Applied Biosystems).
For miRNA detection, RT reactions were performedwith
10 ng of total RNA, 50 nM stem–loop microRNA-specific
RT primers, 1× RT buffer, 0.25 mM of dNTPs, 3.33 U/μl
MultiScribe RTase and 0.25 U/μl RNase inhibitor. The
reaction mixture was incubated for 30 min at 16°C and 30
min at 42°C, followed by 5 min incubation at 85°C to
inactivate the RTase enzyme. RT products were subjected
to microRNA expression assay for real-time quantitative
PCR in a 20-μl final volume containing 2 μl of RT
product, 1 μl of 20× TaqMan® micro-RNA Assay (Applied
Biosystems), and 10 μl of 2× TaqMan® Universal PCR
Master Mix (Applied Biosystems).
qRT-PCR was performed in an ABI Villi 7 Sequence
Detector (Applied Biosystems), and the PCR cycling
parameters were set as follows: 95°C for 10 min followed
by 40 cycles of PCR reactions at 95°C for 20 seconds
and 60°C for 1 min. The expression levels of the BDH2
and LCN2 genes were normalized to the internal control
β-actin to obtain the relative threshold cycle (ΔCT). The
relative expression between CN-AML and controls was
calculated by the comparative CT (ΔΔCT) method. The
CT values of β-actin were controlled between 18 and 22.
Mutation analysis of NPM1, FLT3, CEBPA, mixed lineage
leukemia gene (MLL), IDH1/2 and DNMT3A
BM samples that were collected at diagnosis were retro-
spectively analyzed for gene mutations. Genomic DNA was
extracted from mononuclear cell preparations using an
Illustra™ blood genomicPrep Mini Spin Kit (GE HealthcareUK Limited, UK). The additional molecular markers associ-
ated with AML with normal karyotype, i.e., FLT3-ITD,
FLT3 tyrosine kinase domain (FLT3-TKD) mutation,
NPM1 mutation, CEBPA mutation, isocitrate dehydro-
genase 1/2 (IDH1/2), DNA (cytosine-5)-methyltransferase
3A (DNMT3A) and mixed lineage leukemia gene (MLL)
were screened as previously described [17,24-27].
PCR products were analyzed by agarose gel electro-
phoresis and purified using a QIAquick PCR-purification
kit (Qiagen, Chatsworth, CA, USA). Purified PCR products
were directly sequenced with the forward or reverse
primers of each gene using an ABI BigDye Terminator
Cycle Sequencing Kit (Applied Biosystems) in an ABI Prism
310 DNA sequencer (Applied Biosystems).
Cell culture
The THP1 cell line, an acute myelomonocytic leukemia
cell line, was cultured in RPMI medium (GIBCO, Life
Technologies, Hong Kong) supplemented with 10% fetal
bovine serum (FBS) (GIBCO), 1% penicillin/strepto-
mycin (P/S), 4.5 g/L glucose, 10 mM HEPES (4-(2-
hydroxyethyl)-1-piperazineethane-sulfonic acid), 1 mM
sodium pyruvate, and 1% beta-mercaptoethanol. For
THP1 cells infected with shRNA empty vector and
shRNA-BDH2 lentivirus, 1 μg/mL puromycin (Sigma-
Aldrich, USA) was added as a stress selector.
HL60 cells, an acute promyelocytic leukemia cell line
with t(15;17), were cultured in IMDM medium (GIBCO)
supplemented with 1.5 g/L sodium bicarbonate, 20%
FBS, and 1% P/S. Puromycin (1 μg/mL) was added to
select cells with RNA interference-mediated BDH2-KD.
All cells were cultured at 37°C in a humidified atmos-
phere containing 5% CO2. All native cell lines were
purchased from Food Industry Research and Develop-
ment Institute, Taiwan.
RNA interference-mediated BDH2-KD in THP1 and HL60 cells
The shRNA-BDH2 lentivirus particle was purchased
from Sigma. The clones TRCN0000036735, 0000036736,
0000036738, and 00000244979 were identified as shRNA-
BDH2-1, shRNA-BDH2-2, shRNA-BDH2-3, and shRNA-
BDH2-4, respectively. Naive THP1 and HL60 cells were
transduced with lentiviruses expressing shRNAs and
selected for puromycin resistance (1 μg/mL). The knock-
down efficiency was assessed by qRT-PCR and western
blot analyses.
Statistical analysis
We used software SPSS 17.0 for statistical analysis.
ANOVA was used to compare the differences in BDH2
mRNA expression and LCN2 mRNA expression between
patients with CN-AML, AML-ETO (+) under molecular
studies, inv (16) under cytogenetic study and those with
normal BM. Correlation regression was used for analysis
Figure 1 mRNA expression levels of BDH2 in bone marrow.
BDH2mRNA expression levels in bone marrow from patients with
normal bone marrow and cytogenetically normal AML (CN-AML).
P<0.001. Higher ΔCT-BDH2 means lower mRNA expression levels. BM:
bone marrow. Sample number of bone marrows from normal bone
marrow and CN-AML are 43 and 113.
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pression. We used the receiver operating characteristic
(ROC) curve to estimate the cutoff point for BDH2 to
predict death in CN-AML patients.
Time-to-event analysis involved estimating the prob-
ability that an event would occur at different time
points. The end-point of follow-up for patients who de-
veloped AML was the date of death and for those who
were lost to follow-up was the date of the last visit, to
arrive at “censored” data. Two-sample t-tests and X2
square tests were used to analyze the differences in age,
sex, peripheral white blood cells (WBCs), hemoglobin
(Hb), platelet and blast counts, CD34 and blasts percent-
age in BM, percentage of FLT3-ITD, FLT3-TKD, NPM1
mutations, CEBPA mutation, IDH1/2, DNMT3A and
MLL mutations in the BDH2 low and high expression
groups (BDH2low and BDH2high, respectively) and youn-
ger and older patients group (separate at 60 year-old).
ANOVA were used to analyze ERG, NM1, miR-181a and
miR-3151 in different groups of BDH2 expression and
age. We divided low and high expression of BDH2 using
the median BDH2 expression level (ΔCT-BDH2 = 9.0060),
which was similar to the cutoff point from the ROC
curve prediction (ΔCT-BDH2 = 9.0113). The Kaplan–
Meier estimates were computed for the risk among dif-
ferent categories, were compared by Log-rank tests. The
analysis was performed to estimate the differences in OS
among patients with different BDH levels, and FLT3-
ITD mutation as well as the differences in LFS and RFS
between BDH2high and BDH2low groups.
Two sets of hazard rate ratios (HRR) were computed
for analysis factors by cox regression analyses. The uni-
variate HRRs were estimated from separate Cox regres-
sions with one analysis factor at a time. The factors
included all molecular analyses and other parameters.
The multivariable-adjusted HRRs were computed from
Cox regression with additional variables of the factors
that were identified as being statistically significant in
the univariate analysis.
Apoptosis assay and flow cytometry
We treated THP1 and HL60 cells lines, including shRNA-
BDH2 infected, shRNA empty vector infected, and paren-
tal cells, with 50 μM H2O2 for 30 min and with 15 μM
H2O2 for 30 min, respectively. Then apoptosis was exam-
ined using the ApoScreen™ Annexin V-FITC Apoptosis
Kit (Beckman Coulter, CA, USA). Meanwhile, caspase-3
was also analyzed by flow cytometry in cells treated with
H2O2 using FITC rabbit anti-active caspase-3 (BD
Pharmingen, CA, USA).
Western blot analysis
Cells were treated with 15 and 50 μM H2O2 for 2 h and
were then lysed in cold lysis buffer supplemented withprotease inhibitor cocktails (BioExpress, UT, USA, added
at a 1:100 dilution). Cell lysates were separated by SDS-
PAGE and transferred to a polyvinylidene fluoride mem-
brane (PerkinElmer, Taiwan). Blots were probed with
primary antibodies specific for the following proteins:
PARP, caspase-3, survivin (Cell Signaling Technology,
MA, USA), Bcl-xL, Bax, XIAP (Santa Cruz Biotechnology,
Texas, USA), BDH (Sigma), and β-actin (Millipore
Corporation, MA, USA). After incubation with the
antibody, the proteins were detected with enhanced
chemiluminescence (ECL, PerkinElmer).
JC-1 mitochondrial membrane potential detection
The mitochondrial membrane potential was analyzed
using a MitoProbe™ JC-1 Assay Kit (Life technologies,
CA, USA). The collapse of the electrochemical gradient
across the mitochondrial membrane was measured using a
fluorescent cationic dye, JC-1. This dye exhibits potential-
dependent accumulation in the mitochondrial matrix. Fur-
ther, 1 × 106 cells were incubated with 2 mM JC-1 at 37°C
and 5% CO2 for 30 min. Cells were washed twice with PBS
at 4°C, resuspended in 1 mL PBS, and assessed by a
Beckman Coulter Epics XL.
Results
Association of BDH2 expression with molecular markers
and clinical characteristics
The mRNA expression of BDH2 was higher in patients
with CN-AML and poor risk than in those with normal
BM (P < 0.001, Figure 1 and Additional file 1: Figure
S1). The mRNA expression of LCN2 was lower in
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that we already reported [23]. However, we did not see
difference of BDH2 mRNA expression between good risk
groups and normal bone marrow or CN-AML patients.
There was no correlation between BDH2 and LCN2 ex-
pression (Additional file 2: Figure S2).
We focused on CN-AML patients and used the me-
dian BDH2 mRNA expression level, ΔCT-BDH2 = 9.0060,
as the cutoff point. This value is the same as the cutoff
point predicted by the ROC curve. Among the 113 pa-
tients newly diagnosed with CN-AML, no differences
were observed between BDH2high and BDH2low groups
with regard to clinical features or biological characteris-
tics such as age, sex, WBCs, Hb, platelets, blasts in per-
ipheral blood, blasts in BM, amount of CD34 expression
in BM myeloblasts, and French-American-British (FAB)
classification subtypes (Table 1). Moreover, no differ-
ences were observed with regard to these clinical fea-
tures between the 2 groups, among the 86 patients with
CN-AML with intensive induction chemotherapy (data
not shown).
The incidences of common genetic alterations in the
BDH2high and BDH2low groups are shown in Table 2. On
the whole cohort analysis, our patients showed similar
incidences of FLT3-ITD and FLT3-TKD mutations when
compared with data from Taiwan National University
[28]; however, the incidences of NPM1, MLL and CEBPA
mutations were higher and the incidence of IDH1 muta-
tion was lower. FLT3-ITD showed a higher mutation
rate in the BDH2high group (P = 0.030, Table 2) and
DNMT3A showed a higher mutation rate in the BDH2low
group (P = 0.009, Table 2). We did not observe differences
in NPM1, FLT3-TD, CEBPA, and IDH1/2 mutations be-
tween the 2 groups (Table 2).
Gene alternations frequencies between younger and
elder patients
As shown in Table 3, the frequency of FLT3-TKD muta-
tion is higher in patients more than 60 years-old. And
the CEBPA double mutation rate is higher in younger
patients group. There are no different of NPM1, FLT3-
ITD, IDH1/2, DNMT3A and MLL gene mutations, and
no difference in BDH2, ERG, MN1, miR-181a and
miR-3151 expression levels, between different age
group.
BDH2 expression as a prognostic marker
We analyzed 86 patients who received a standard inten-
sive chemotherapy. In response rate analysis, patients in
the BDH2high group showed a lower complete response
rate (60%) than those in the BDH2low group (80.42%).
However, no difference was observed between the 2
groups with respect to the time required to reach a
complete response (Table 1). We also analyzed completeresponse (CR) rate based on genetic alterations and no-
ticed that patients with DNMT3A mutations had signifi-
cant higher CR rate than patients without DNMT3A
mutation (P = 0.012). We did not find significant differ-
ence in CR rate between FLT3-ITD, NPM1, CEBPA and
IDH1/2 mutations (data not shown). Results of the sur-
vival analysis showed that patients in the BDH2high
group had a lower overall survival (OS) with a medium
survival of 9 months than those in the BDH2low group
with a median survival of 53.667 months (P = 0.007,
Figure 2A). However, we did not note any difference in
the LFS rates between the BDH2high and BDH2low
groups, with median survivals of 12.033 months and
13.2 months, respectively (P = 0.730, Figure 2B).
In univariate analysis of the impact factors on OS, old
age, high BDH2 expression, and FLT3-ITD mutation ad-
versely affected OS with statistical significance (P = 0.001,
0.007, and < 0.001, respectively; Table 4). NPM1, FLT2-
TKD, CEBPA, IDH1/2, DNMT3A and MLL mutations did
not show impact on OS. Multivariate analysis showed that
FLT3-ITD, FLT3-TKD and MN1 mutations adversely af-
fected RFS. While NPM1 mutation showed positive im-
pact on RFS. High BDH2 expression had a mild adverse
effect on RFS without statistical significance. However, a
significant, independent adverse impact of high BDH2 ex-
pression, FLT3-ITD mutation, MN1 mutation, and old age
were observed in the OS multivariate analysis (Table 5). In
patients with 60 year-old or younger, FLT3-ITD, FLT3-
TKD, MN1 mutations, and ERG and BDH2 higher expres-
sion level showed adverse impact on survival. In elder
patients, we saw ERG and BDH2 higher expression
level had poor survival (Table 6). No patients in elderly
group had DNMT3A mutation.
By combining two independent prognostic factors,
BDH2 expression and FLT3-ITD mutation, we found
that patients with BDH2lowFLT3-ITD-wild type had the
highest OS, with a median survival surpassing 10 years.
On the other hand, patients with BDH2highFLT3-ITD-
mutation had the worst overall survival, with a median
survival of 3.833 months. We observed significant dif-
ferences in the overall survival between the BDH2 ex-
pression groups with and without the FLT3-ITD
mutation (median survival: BDH2lowFLT3-ITD-wild
type vs. BDH2highFLT3-ITD-wild type vs. BDH2lowFLT3-
ITD-mutation vs. BDH2highFLT3-ITD-mutation = not
reached vs. 18.567 months vs. 6.2 months vs. 3.833
months, P < 0.001, Figure 2C and 2D).
We analyzed 22 patients who received allogeneic
hematopoietic stem cell transplantation, including 14 pa-
tients in the BDH2 lower expression group and 8 in the
BDH2 higher expression group. Though there was no
statistically significant difference, we saw a trend of lon-
ger survival from hematopoietic stem cell infusion in the
BDH2low group (P = 0.520, Additional file 3: Figure S3).








Sexb 113 57 56 0.467
Male 64 23 26
Female 49 34 30
Age (years)c 54.5 (21–86) 48 (22–86) 57 (21–85) 0.193
Laboratory datac
WBC, ìL−1 30,830 37,615 24,370 (600–243,290) 0.452
(300–296,300) (300–216,820)
Hb, g/dL 8.3 8.3 8.4 0.365
(4.2–15.6) (4.4–14.3) (4.2–15.6)
Platelet, ×1,000/ìL 42 44.5 41 0.582
(3–369) (4–175) (3–369)
Blast, ìL−1 20,188.5 13,074.15 26,001 0.172
(0–287,411) (126–145,572.7) (0–287,411)
Blast in BM, % 74.8% (24.8%–97.4%) 70.8% (24.8%–94.7%) 79% (27.2%–94.4%) 0.424
CD34 (+) in BM, % 31.1% 29.5% 33.25% (0%–99.5%) 0.272
(0%–99.9%) (0%–99.9%)
FABb
M0 3 1 (1.75%) 2 (2.44%) 0.057
M1 28 8 (13.89%) 20 (43.90%)
M2 47 25 (47.23%) 22 (34.15%)
M3 0 0 (0%) 0 (0%)
M4 23 15 (23.61%) 9 (14.63%)
M5 7 6 (9.72%) 1 (0%)
M6 0 0 (0%) 0 (0%)
M7 4 2 (2.78%) 2 (4.88%)
Undetermined 0 0 (0%) 0 (0%)
Induction responsebd
CR 61 (70.93%) 37 (80.42%)f 24 (60%)g 0.032*
PR and Refractory 32 20
Induction death 1 0
Reach CR timee
38 ± 38.0 40.5 ± 44.3 36 ± 29.7 0.526
aThe median value of BDH2 expression in the total population was used as the cutoff level of 9.006 to define low- and high-expression groups.
bNumber of patients (%).
cMedian (range).
dOnly the 86 patients who received conventional intensive induction chemotherapy, and then consolidation chemotherapy if CR was achieved, were included in
the analyses.
ePatients received conventional intensive induction chemotherapy and achieved CR, median, days ± S.D.
fOnly 46 patients received I3A7.
gOnly 40 patients received I3A7 (Idarubicin and Ara-C).
*Statistically significant (P < 0.05).
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in BDH2-KD cells under hyperoxidative stress via a
caspase-3-independent pathway
Reactive oxygen species (ROS) can induce apoptosis [29].
Devireddy et al. showed that the apoptosis rate increasedin BDH2-KD FL5.12 cells upon H2O2 treatment [22]. The
impact of BDH2 was evaluated by using RNA interference-
mediated BDH2-KD in THP1 and HL60 leukemia cell
lines. The efficacy of BDH2-KD was confirmed at both
RNA (Figure 3A and 3B) and protein levels (Figure 4B).
Table 2 Comparison of other genetic alterations between AML patients in low and high BDH2 expression groups
Variant Number of patients with the gene alternation (percentage) P
Whole cohort Low BDH2, expression High BDH2, expression
NPM1mut 36 (31.85%) 16 (28.07%) 20 (35.71%) 0.271
FLT3-ITD 23 (20.35%) 7 (12.28%) 16 (28.57%) 0.030*
FLT3-TKD 8 (7.08%) 5 (8.77%) 3 (5.36%) 0.338
NPM1mut/FLT3-ITDneg 20 (17.70%) 11(19.30%) 9 (16.07%) 0.368
CEBPAa 34 (30.09%) 16 (28.07%) 18 (32.14%) 0.444
CEBPADouble mutation 9 (7.96%) 3 (5.26%) 6 (10.71%) 0.593
IDH1b 3 (3.75 %) 1 (2.56 %) 2 (4.88%) 0.592
IDH2b 8 (10 %) 3 (7.69%) 5 (12.20%) 0.508
DNMT3Ab 12 (15 %) 10 (25.641%) 2 (4.88%) 0.009*
MLLb 7 (8.75%) 3 (7.69%) 4 (9.76%) 0.426
ERGc 11.17 (10.26-12.08) 11.60 (10.48-12.72) 10.68 (9.17-12.20) 0.320
MN1c 12.98 (12.28-13.68) 13.35 (12.42-14.28) 12.55 (11.47-13.64) 0.257
miR-181ac 3.12 (2.57-3.67) 3.17 (2.35-3.98) 3.07 (2.30-3.84) 0.864
miR-3151c 12.35 (11.90-12.80) 12.18 (11.53-12.84) 12.53 (11.89-13.16) 0.448
Values are number (%) of patients with alteration.
aCEBPA single and double mutations.
bOnly 80 patients with high quality of DNA to sequence; 39 patients are low BDH2 expression and 41 patients are high expression.
cMean (95% CI).
*Statistically significant (P < 0.05).
Table 3 Comparison of other genetic alterations between older and younger AML patientsa
Variant Number of patients with the gene mutation (percentage); Median of RNA expression (delta CT) P
Whole cohort 60 years or younger, (n=69) Older than 60 y/o, (n=44)
NPM1mut 38 (33.33%) 21 (30%) 17 (38.64%) 0.227
FLT3-ITD 23 (20.18%) 15 (21/43%) 8 (18.18%) 0.433
FLT3-TKD 8 (7.02%) 2 (2.86%) 6 (13.64%) 0.036*
NPM1mut/FLT3-ITDneg 22 (19.30%) 11(15.71%) 11 (25%) 0.164
CEBPAa 34 (30.36%) 18 (26.09%) 16 (37.20%) 0.151
CEBPADouble mutation,b 9 (78.04%) 8 (11.59%) 1 (2.23%) 0.016*
IDH1c 3 (3.75 %) 2 (4%) 1 (3.3%) 0.686
IDH2c 8 (10 %) 4 (8%) 4 (13.2%) 0.454
DNMT3Ac 12 (15 %) 10 (25.641%) 2 (4.88%) 0.095
MLL 7 (8.75%) 4 (8%) 3 (10%) 0.528
Delta BDH2d 9.006 (4.53-12.36) 9.051 (4.53-12.36) 8.915 (6.4-12.15) 0.102
ERGd 10.595 (4.52-19.92) 10.88 (5.17-19.92) 9.74 (4.52-19.85) 0.435
MN1d 13.25 (7.75-19.87) 13.06 (7.76-19.87) 13.25 (7.75-18.38) 0.992
miR-181ad 3.21 (−3.8-8.44) 3.3 (−0.03-8.44) 2.49 (−3.8-8.2) 0.140
miR-3151d 12.685 (4.97-15.29) 12.685 (9.16-15.07) 12.6 (4.97-15.29) 0.247
Values are number (%) of patients with alteration.
aCEBPA single and double mutations.
bCEBPA double mutation vs CEBPA single mutation vs no mutation.
cOnly 80 patients with high quality of DNA to sequence; 50 patients are 60 y/o or younger patients and 30 patients are high expression.
dMedian delta CT(range).
*Statistically significant (P < 0.05).
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Figure 2 Outcome of patients with CN-AML according to BDH2 expression levels and FLT3-ITD mutation status. In 85 patients receiving
intensive induction chemotherapy, we analyzed A) overall survival; B) leukemia-free survival between 2 different BDH2 expression groups; and C)
overall survival; D) leukemia-free survival between groups differentiated by BDH2 expression level, combined with the FLT3-ITD mutation status.
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that shRNA-BDH2-3 HL60 had more apoptotic cells
(Additional file 4: Figure S4). This result was con-
firmed by Annexin V/PI staining analysis. Figure 5
shows the apoptotic population in different levels of
BDH2-KD HL60 cells. After H2O2 treatment, BDH2-
KD HL60 cells showed a more prominent increase in
the secondary and forth quadrant, indicating that
BDH2 exerted an anti-apoptotic effect (Figure 5). The
same effect was also observed in BDH2-KD THP1 cells
(data not shown). Nevertheless, the conventional
apoptosis-related proteins, including PARP, caspase-3,
Bcl-xL, Bcl-2 and Bax, did not mediate H2O2-induced
apoptosis in BDH2-KD HL60 cells (Figure 4B). Western
blotting data also failed to show caspase-3 activation using
flow cytometry analysis (Figure 4A), regardless of whether
the expression level of BDH2 was high or low. Taken to-
gether, the results did not show a correlation between
BDH2-KD and the activation of the Bcl-2/Bcl-xL-medi-
ated intrinsic pathway via the caspase cascade to trigger
apoptosis. This phenomenon correlated with mitochon-
drial membrane potential analysis (Additional file 5:
Figure S5).
There is a family of functionally and structurally re-
lated proteins that serve as endogenous inhibitors ofapoptosis (IAP) [30]. Survivin, the smallest member of
the IAP family, increases during ROS stimulation to pro-
tect cells from apoptosis [30,31]. A marked induction of
survivin upon H2O2 treatment was observed in our
study, whereas XIAP was not altered in cells with differ-
ent BDH2 expression levels. Of note, the induction of
survivin was abrogated in shRNA-BDH2-3 HL60 cells.
These data suggest that survivin is responsible for ele-
vating the apoptosis rate upon ROS treatment in BDH2-
KD cells.
Discussion
The prognosis of CN-AML depends on the molecular
status (e.g., FLT3, NPM1, CEBPA, IDH1/2, DNMT3A,
MLL, ERG, MN1 and micro-RNA-181a and 3151); how-
ever, not all candidate markers have been detected so
far. Energy metabolism differs in normal cells and cancer
cells. Inborn errors of metabolism can induce cancer de-
velopment [32]. Cancer can also result from deficiency
or overactivity of enzymes, deficiency of a cofactor re-
quired for enzymatic activity, an abnormality in degrad-
ation or transport processes that lead to the accumulation
of upstream metabolites, deficiency of a downstream me-
tabolite, or diversion of the affected metabolic flux to sec-
ondary pathways [33].
Table 4 Univariate analyses of the impact on overall







60 or younger 66 32.2
Older than 60 22 4.5
WBC 0.469
50000/uL or less 49 31.433
Greater than 50000/uL 37 13
BDH2 0.007*
Lower expression 46 53.667
Higher expression 40 9
CEBPA 0.755
Double mutation 9 31.433
Single mutation 16 53.667


























BDH2low/FLT3-ITDwild type 40 722.16
BDH2low/FLT3-ITDmutation 5 519.73
Table 4 Univariate analyses of the impact on overall
survival in patients with CN-AML who received intensive
induction chemotherapy (Continued)
BDH2high/FLT3-ITDwild type 27 371.56
BDH2high/FLT3-ITDmutation 13 182.27
Abbreviation: NR indicates not reached.
aMedian, months.
bOnly 64 patients who had high quality DNA preserved for sequence received
standard intensive induction chemotherapy.
*Statistically significant (P < 0.05).
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born errors of metabolism: (1) toxic accumulation of
metabolites, (2) metabolite channeling, and (3) mito-
chondrial dysfunction. Toxin accumulation leads to an
increase in oxidative stress and ROS, as seen with iron ac-
cumulation in hemochromatosis [34]. In addition, accu-
mulation of toxic metabolites could affect gene expression
or cause a shift to alternative metabolic pathways, which
could lead to tumorigenesis [29].
Human BDH2 (DHRS6) is an enzyme that participates in
the citric acid cycle metabolism and ketogenesis [32], which
may play a crucial role in promoting tumorigenesis [33,34].
In our results, BDH2 mRNA expression was higher in the
BM of patients with CN-AML and AML with multiple
chromosome abnormalities, compared with normal BM
samples. We focused on CN-AML patients. No differences
were observed in the incidence of clinical pictures, includ-
ing blast amount in BM, FAB classification, and alterations
in genes, except FLT3-ITD and DNMT3A, between
BDH2high and BDH2low groups. High BDH2 expression is
an independent indicator of poor prognosis of CN-AML,
which may be related to a poor response to conventional
intensive chemotherapy and a low CR rate. Given the inde-
pendent adverse impact on survival and the low response
rate in patients in the BDH2high group in both younger and
elder patients, we suggest that higher BDH2 expression
makes patients resistant to intensive induction chemother-
apy. Although high BDH2 expression does not shorten the
duration of relapse once patients obtain CR, patients with
low BDH2 expression may benefit from further treatment,
including chemotherapy and allogenetic hematopoietic
stem cell transplantation, which may prolong survival time.
In outcome analysis by gene alternations, FLT3-ITD
and MN1 mutations, and BDH2 were independent adverse
prognostic factor for survival, with statistics significant.
ERG and MLL mutations, and higher miR-3151 expression
level showed a trend of adverse impact on survival. NPM1,
CEBPA mutations and miR-181a showed positive out-
come in CN-AML patients. However, DNMT3A muta-
tions showed a good impact on survival, that could not
compatible with previous reports. The mutations in
DNMT3A in eleven of twelve of our patients are R882
(4279129C->T). One patient with DNMT3A mutation is
R882 (4279073G->T). Only 12 CN-AML patients have
Table 5 Multivariate analyses (cox regression) of relapse-free survival and overall survivala
Variables
Relapse-free survival Overall survival
95% CI 95% CI
HR Lower Upper P HR Lower Upper P
Whole cohort (n = 86)
Ageb 3.083 0.184 51.762 0.434 3.252 1.322 8.002 0.010*
NPM1c 0.087 0.012 0.604 0.014* 0.392 0.128 1.195 0.100
FLT3-ITDd 21.079 1.427 311.302 0.026* 4.532 1.395 14.723 0.012*
FLT3-TKD 19.630 1.539 250.445 0.022* 1.801 0.184 17.603 0.613
CEBPAe 0.408 0.144 1.154 0.091 0.398 0.147 1.080 0.070
IDH1c 0.448 0.039 5.167 0.520 0.648 0.128 3.268 0.599
IDH2c 0.583 0.025 13.640 0.737 0.254 0.036 1.781 0.168
DNMT3Ac 0.292 0.041 2.098 0.221 0.731 0.158 3.380 0.689
MLL c 31.310 0.729 1344.29 0.073 1.040 0.215 5.020 0.961
MN1 1.391 1.027 1.883 0.033* 1.195 1.025 1.394 0.023*
ERG 5.799 0.548 61.325 0.144 2.545 0.993 6.520 0.052
miR-181a 0.824 0.598 1.135 0.236 0.860 0.692 1.069 0.174
miR-3151 1.183 0.750 1.867 0.469 1.285 0.884 1.866 0.189
BDH2f 2.035 0.472 8.782 0.341 2.547 1.094 6.685 0.050*
Abbreviations: HR indicates Hazard ratio; CI, confidence interval.
aOnly patients with intensive induction chemotherapy enrolled.
bAge > 60 relative to Age ≤ 60 (the reference).
cNPM1mut versus NPM1wild type; IDH1mut versus IDH1wild type; IDH2mut versus IDH2wild type; DNMT3Amut versus DNMT3Awild type ; MLLmut versus MLLwild.
dFLT3-ITDmut versus FLT3-ITDneg.
eCEBPAdouble-mutation versus CEBPAsingle mutation versus CEBPAno mutation.
fBDH2high relative to BDH2low group.
*Statistically significant (P < 0.05).
Table 6 Multivariate analyses (cox regression) of overall survivala in younger and older patients
Variables
Patients ≦ 60 y/o Patients > 60 y/o
95% CI 95% CI
HR Lower Upper P HR Lower Upper P
NPM1b 0.000 0.000 1.490E89 0.898 0.263 0.021 3.377 0.305
FLT3-ITDc 7.505 1.538 36.614 0.013* 3.235 0.424 24.699 0.258
FLT3-TKD 9765.104 32.249 2.95E6 0.002* 144.617 0.000 3.75E169 0.980
CEBPAd 0.357 0.125 1.020 0.054 1.090 0.292 4.066 0.898
IDH1b 14220.871 0.000 3.9E99 0.932 174.990 0.000 4.56E169 0.979
IDH2b 0.000 0.000 2.695E210 0.958 0.459 0.050 4.242 0.492
DNMT3Ab 146.313 0.000 4.16E97 0.965
MLLb 0.059 0.000 1.78E94 0.980 2.245 0.173 29.122 0.536
MN1e 1.923 1.130 3.273 0.016* 1.198 0.916 1.567 0.187
ERG 53.777 1.820 1589.377 0.021* 32.349 2.889 362.237 0.005*
miR-181a 0.514 0.260 1.014 0.055 1.361 0.933 1.986 0.110
miR-3151 1.164 0.580 2.337 0.669 0.423 0.191 0.935 0.033*
BDH2e 4.829 1.002 23.274 0.050* 18.937 1.571 228.308 0.021*
Abbreviations: HR indicates Hazard ratio; CI, confidence interval.
aOnly patients with intensive induction chemotherapy enrolled.
bNPM1mut versus NPM1wild type; IDH1mut versus IDH1wild type; IDH2mut versus IDH2wild type; DNMT3Amut versus DNMT3Awild type.
cFLT3-ITDmut versus FLT3-ITDneg.
dCEBPAdouble-mutation versus CEBPAsingle mutation versus CEBPAno mutation.
eBDH2high relative to BDH2low group.
*Statistically significant (P < 0.05).
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Figure 3 shRNA interference-mediated knockdown efficiency in leukemia cell lines. BDH2 mRNA expression level in BDH2-knockdown,
control vector infected, and parental cells. A) THP1 cells and B) HL60 cells, as determined by qRT-PCR analyses.
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http://www.jbiomedsci.com/content/20/1/58DNMT3A mutation. Because of small number of patients,
we cannot say that DNMT3A mutations had positive im-
pact in overall survival (OS) in our patients. And that is
the reasons of non-significant impact of other well-known
genes alternations in CN-AML in our study.
To test if BDH2 can induce chemoresistance, we gen-
erated BDH2-KD leukemia cell lines. Oxidative damage
is thought to be an important mechanism by which
agents such as alkylators can damage DNA [35]. The in-
tensive chemotherapy agents we used were cytarabine
and idarubicin, which is an anthracycline. Cytarabine is
an antimetabolic agent that causes DNA damage when
the cell cycle holds in the S-phase [35]. Anthracycline
kills leukemia cells via 3 mechanisms: inhibiting DNA
and RNA synthesis by intercalating between base pairs
of the DNA/RNA strand; inhibiting topoisomerase II en-
zyme, preventing the relaxation of supercoiled DNA,
and thus blocking DNA transcription and replication;
and creating iron-mediated free oxygen radicals that
damage DNA and cell membranes [36]. In our study,
BDH2-KD cells were more sensitive to ROS stimulation
and more susceptible to apoptosis than parental and
shRNA control vector transfected cells. Among the reg-
ulators of programmed cell death, or apoptosis, mem-
bers of the Bcl-2 family control the release of
apoptogenic proteins from mitochondria [37], whereas
members of the IAP gene family act as endogenous inhibi-
tors of caspases [38]. No difference was observed between
Bcl-2 and Bcl-XL expression in parental, control vector,
and BDH2-KD leukemia cell lines, before or after H2O2
treatment. The data showed that survivin was less in
BDH2-KD cells than control cells, after ROS stimulation,
but did not change before ROS stimulation. The other
IAP, XIAP, did not differ significantly between BDH2-KD
and control cells, before or after ROS stimulation. We also
observed a limited increase in the cleaved form of
caspase-3 in BDH2-KD cells by flow cytometry analysis.
Survivin, the smallest member of the IAP family, has a
synergic effect with XIAP in cytoprotection [39]. Survivininhibits active caspase-9, but not active caspase-3 [40].
Survivin is selectively expressed in most human cancers,
including lung, breast, pancreatic, and colon carcinomas;
soft tissue sarcomas; brain tumors; melanoma; neuroblast-
oma; and hematologic malignancies [40]. We observed
that BDH2-KD cells had a higher apoptotic rate under
ROS stimulation, mediated by suppression of survivin re-
lease after ROS exposure.
Here, we showed that BDH2 overexpression could
shorten overall survival and decrease the response rate
from intensive induction chemotherapy. The mechanism
by which BDH2 works as an anti-apoptotic factor is me-
diated by survivin through a caspase-3 independent
pathway. To the best of our knowledge, we are the first
to report that BDH2 is newly identified as a poor inde-
pendent prognostic factor for CN-AML. Lower respon-
siveness to chemotherapy is predicted and hematological
stem cell transplantation should be considered for pa-
tients with high expression of BDH2. The limitations of
our work are related small patients’ number and not
purify leukemia or CD34 (+) hematopoietic cells while
collected bone marrow samples. We did not find differ-
ence of CD34 content in bone marrow samples between
BDH2 higher and lower expression groups. On the other
hand, we performed a study to induce THP1 to mature
monocytes by using 1,25 Vitamine D3, and detect the
BDH2 mRNA expression level. We did not find differ-
ence in native THP1 cells and mature treated THP1 cells
(data not shown) [23].
In our future work, we will enroll more AML patients,
especially patients receiving hematological stem cell
transplantation to analysis the impact of BDH2. We will
prospectively collect bone marrow from AML patients
and sort CD34+ hematopoietic cells and perform those
experiments for analysis prognosis. On the other hand,
since BDH2 is an anti-apoptosis factor, we will analyze
its impact with other factors which are related
to apoptosis, like Wilms tumor 1 [41], and DNA
methyltransferase 3 [42].
Figure 4 Caspase-3 activity after treatment with 50 μM H2O2 for 2 h in the HL60 cell line. A) Cleaved caspase-3 detected by flow
cytometry. The gray area represents cells that were not subjected to the H2O2 treatment, and the dot- lines denote cells treated with H2O2. Top
left: parental HL60; top right: shRNA-BDH2-2 HL60; bottom left: shRNA-BDH2-3 HL60; bottom right: shRNA control vector HL60. B) Bcl-2, Bcl-xL,
BAX, PARP, survivin, XIAP, and BDH2 protein expression on a western blot analyses.
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Figure 5 Apoptosis rate in HL60 cells after treatment with 50 μM H2O2 for 2 h. The apoptosis rate was dependent on the BDH2-
knockdown efficiency: A) shRNA-BDH2-1 HL60; B) shRNA-BDH2-2 HL60; C) shRNA-BDH2-3 HL60; D) shRNA-BDH2-4 HL60; and E) shRNA control
vector HL60; F) the apoptosis rate of each cell lines. Dark gray: late apoptosis bar; light gray bar: early apoptosis.
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We reported that BDH2 overexpression could shorten
overall survival and decrease the response rate from in-
tensive induction chemotherapy. The mechanism by
which BDH2 works as an anti-apoptotic factor is medi-
ated by survivin through a caspase-3 independent
pathway.
Additional files
Additional file 1: Figure S1. mRNA expression levels of BDH2 in bone
marrow. BDH2mRNA expression levels in bone marrow from patients
with normal bone marrow, cytogenetically normal AML (CN-AML), good
risk patients with AML-ETO fusion gene and chromosome inv (16), and
poor risk patients with multiple chromosome abnormalities. P<0.001.
Higher ΔCT-BDH2 means lower mRNA expression levels. BM: bone marrow.
Sample number of bone marrows from normal bone marrow, CN-AML,
AML with AML-ETO (+), AML with inv (16), and AML with multiple
chromosome abnormalities are 43, 113, 10, 3 and 25.
Additional file 2: Figure S2. Correlation between BDH2 and LCN2
mRNA expression in bone marrow. There is no correlation between the
mRNA expression of BDH2 and LCN2.
Additional file 3: Figure S3. The Kaplan-Meier overall survival curves in
different BDH2 expression groups. HSCT indicates hematopoietic stem
cell transplantation.
Additional file 4: Figure S4. Apoptosis after 50 μM H2O2 treatment for
2 h in each cell line, assessed under a light microscope at 200×. Blue
arrows indicate apoptotic cells. shRNA-BDH2-3 HL60 cells had more
apoptotic cells.
Additional file 5: Figure S5. The mitochondrial membrane potential
change. That was analyzed using a MitoProbe™ JC-1 Assay Kit and no
difference between BDH2-knockdown THP1 cells and control cells. shRNA1,
shRNA-BDH2-1 THP1; shRNA3, shRNA-BDH2-3 THP1; shRNAc, shRNA empty
vector infected THP1; CCCP, carbonyl cyanide 3-chlorophenylhydrazone,
positive control.Abbreviations
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